$664.5 M

DVAX Mkt cap, 04-Dec-2018

$1.5 M

Dynavax Technologies Revenue Q3, 2018
Dynavax Technologies Net income (Q3, 2018)-40.5 M
Dynavax Technologies EBIT (Q3, 2018)-38.9 M
Dynavax Technologies Cash, 30-Sep-201838.7 M
Dynavax Technologies EV726.1 M

Dynavax Technologies Revenue Breakdown

Embed Graph

Dynavax Technologies revenue breakdown by business segment: 8.0% from Service and license revenue, 88.5% from Collaboration revenue and 3.5% from Other

Dynavax Technologies Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

11.3m11.0m4.1m11.0m327.0k

Revenue growth, %

(2%)(63%)173%

R&D expense

50.9m84.6m86.9m84.5m65.0m

General and administrative expense

25.9m17.4m22.2m37.3m27.4m

Operating expense total

77.7m102.0m109.1m121.8m96.3m

Depreciation and amortization

1.2m

EBIT

(66.5m)(91.3m)(105.1m)(110.7m)(96.0m)

EBIT margin, %

(591%)(828%)(2594%)(1003%)(29359%)

Interest expense

35.0k572.0k

Interest income

116.0k191.0k205.0k755.0k1.3m

Net Income

(66.7m)(90.7m)(106.8m)(112.4m)(95.2m)

Dynavax Technologies Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

23.1m49.5m44.8m24.3m26.6m

Accounts Receivable

1.6m727.0k1.4m

Inventories

1.4m4.1m2.4m6.8m312.0k

Current Assets

192.4m127.4m199.9m89.6m198.0m

PP&E

8.7m7.9m13.8m17.2m16.6m

Goodwill

2.6m2.3m2.0m2.0m2.2m

Total Assets

204.6m138.3m216.6m109.7m218.8m

Accounts Payable

1.9m1.2m3.4m3.8m4.5m

Short-term debt

Current Liabilities

16.2m20.3m28.8m20.0m18.6m

Long-term debt

9.6m

Non-Current Liabilities

2.1m17.5m769.0k443.0k

Total Debt

9.6m

Total Liabilities

18.3m37.8m29.6m20.5m19.2m

Additional Paid-in Capital

688.4m695.1m889.7m905.0m1.1b

Retained Earnings

(502.2m)(592.9m)(699.7m)(812.2m)(907.3m)

Total Equity

186.3m100.5m187.1m89.2m199.5m

Debt to Equity Ratio

0.1 x

Debt to Assets Ratio

0.1 x

Financial Leverage

1.1 x1.4 x1.2 x1.2 x1.1 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

12.2m26.8m17.0m19.7m14.7m36.5m103.0m38.9m24.8m23.0m21.5m37.7m20.1m36.1m28.7m38.7m

Accounts Receivable

2.2m1.7m1.3m727.0k909.0k657.0k1.2m1.2m

Inventories

550.0k5.1m12.5m

Current Assets

79.8m181.7m160.6m134.9m102.0m97.9m224.3m170.7m147.1m117.5m89.7m132.2m197.1m255.4m226.3m198.8m

PP&E

8.5m8.6m8.8m8.1m7.5m8.9m11.6m15.9m17.4m18.7m16.6m16.8m16.6m17.1m16.2m16.9m

Goodwill

2.5m2.6m2.6m2.4m2.0m2.1m2.1m2.1m2.1m2.1m2.0m2.1m2.2m2.3m2.2m2.2m

Total Assets

91.7m193.6m173.5m146.9m112.2m109.5m238.9m189.6m167.6m139.3m110.1m152.0m217.8m295.3m263.9m236.4m

Accounts Payable

1.3m1.9m1.9m5.0m3.3m2.3m2.4m3.5m4.5m3.8m1.5m681.0k2.2m2.3m3.3m4.1m

Current Liabilities

15.6m16.0m20.2m22.8m20.5m22.0m19.7m24.5m28.2m30.5m12.4m11.1m12.9m23.5m25.5m31.6m

Long-term debt

8.9m8.0m9.6m99.2m99.8m100.3m

Total Debt

8.9m8.0m9.6m99.2m99.8m100.3m

Total Liabilities

19.3m19.7m22.8m25.3m37.1m35.0m27.7m25.2m28.8m31.0m12.7m11.4m13.4m129.4m132.6m139.4m

Additional Paid-in Capital

561.7m689.7m691.4m693.1m697.1m720.0m886.6m893.3m897.0m901.1m938.2m1.0b1.1b1.1b1.1b1.1b

Retained Earnings

(489.2m)(516.1m)(540.8m)(570.6m)(619.1m)(642.7m)(672.9m)(726.7m)(755.7m)(790.4m)(837.5m)(857.8m)(879.9m)(946.3m)(985.7m)(1.0b)

Total Equity

74.5m211.2m164.4m138.8m108.3m97.4m140.5m204.4m165.9m131.3m97.0m

Debt to Equity Ratio

0.1 x0 x0.6 x0.8 x1 x

Debt to Assets Ratio

0.1 x0 x0.3 x0.4 x0.4 x

Financial Leverage

1.5 x1.1 x1.2 x1.2 x1.3 x1.1 x1.1 x1.1 x1.8 x2 x2.4 x

Dynavax Technologies Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(66.7m)(90.7m)(106.8m)(112.4m)(95.2m)

Depreciation and Amortization

1.3m1.4m1.4m2.3m3.2m

Accounts Receivable

(622.0k)900.0k(667.0k)52.0k

Inventories

677.0k(2.7m)1.6m560.0k(312.0k)

Accounts Payable

(657.0k)(523.0k)1.2m1.2m(1.9m)

Cash From Operating Activities

(58.7m)(73.7m)(92.6m)(107.1m)(77.5m)

Purchases of PP&E

(669.0k)

Cash From Investing Activities

(51.4m)90.6m(85.8m)86.2m(108.7m)

Cash From Financing Activities

125.4m9.9m174.0m531.0k187.8m

Interest Paid

720.0k720.0k

Dynavax Technologies Ratios

USDY, 2018

EV/EBIT

-18.7 x

EV/CFO

-7.4 x

Debt/Equity

1 x

Debt/Assets

0.4 x

Financial Leverage

2.4 x
Report incorrect company information

Dynavax Technologies Operating Metrics

FY, 2016

Patents (Foreign)

260

Patents (US)

30

Patents Pending

40

Phase I Trials Products

2

Phase II Trials Products

3

Phase III Trials Products

1

Preclinical Phase Products

2
Report incorrect company information

Dynavax Technologies Employee Rating

3.328 votes
Culture & Values
3.0
Work/Life Balance
3.7
Senior Management
3.5
Salary & Benefits
2.9
Career Opportunities
2.7
Source